Please login to the form below

Not currently logged in
Email:
Password:

Ablynx reaches third Alzheimer's milestone

Boehringer Ingelheim has made a €5m milestone payment to Ablynx following the continued development of its nanobody candidate

Boehringer Ingelheim has made a €5m milestone payment to Ablynx following the continued development of its nanobody candidate.

In January 2007, Boehringer and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's nanobodies against a single disease target.

The collaboration has a potential value of $265m in upfront and milestone payments and undisclosed royalties on product sales.

Boehringer is responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.

Dr Edwin Moses, chairman and chief executive of Ablynx, said: "We are delighted that Boehringer Ingelheim is making further progress with the nanobody lead candidate which has the potential to be a first-in-class therapy for Alzheimer's disease and we look forward to this product advancing into the clinic in 2012."

It is the second milestone payment that Ablynx has received as part of its Alzheimer's research collaboration with Boehringer.

30th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...